When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis

Código QR

When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis

Norman J KachuckUniversity of Southern California, Keck School of Medicine, Los Angeles, CA, USAAbstract: New more powerful therapies for the treatment of multiple sclerosis may also confer a potential for unprecedented life-endangering side effects. How does a physician respond to a patient&amp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Kachuck NJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/be798b95f75e4e0ba2267b0d1476072e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Kimberley Allen-Philbey, et al.
Publicado: (2021)

A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis
por: Kerstin Hellwig, et al.
Publicado: (2021)

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report
por: Afsaneh Shirani, et al.
Publicado: (2021)

Prevalence of Pediatric Onset Multiple Sclerosis in Saudi Arabia
por: Reem Bunyan, et al.
Publicado: (2021)

A neurologist’s rhombencephalitis after comirnaty vaccination. A change of perspective
por: Alexander Walter, et al.
Publicado: (2021)

Do neurologists in Germany adhere to the national Parkinson&#39;s disease guideline?
por: Sabrina Schr&ouml;der, et al.
Publicado: (2011)

Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets
por: Christoph Grothe, et al.
Publicado: (2021)

The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results
por: Sandra Thiel, et al.
Publicado: (2021)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes KC
Publicado: (2011)

Attention deficits in Japanese multiple sclerosis patients with minor brain lesion loads
por: Takeda A, et al.
Publicado: (2011)

Walking impairment in patients with multiple sclerosis: exercise training as a treatment option
por: Robert W Motl, et al.
Publicado: (2010)

The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis
por: Aliza Bitton Ben-Zacharia, et al.
Publicado: (2021)

The hospital anxiety and depression scale, in patients with multiple sclerosis
por: Pais-Ribeiro JL, et al.
Publicado: (2018)

Cognitive dysfunction in pediatric multiple sclerosis
por: Suppiej A, et al.
Publicado: (2014)

The Multiple Sclerosis Treatment Optimization Program
por: Annette Langer‐Gould, et al.
Publicado: (2021)

Cognitive status in patients with multiple sclerosis in Lanzarote
por: Pérez-Martín MY, et al.
Publicado: (2016)

Psychiatrists’ Understanding and Management of Conversion Disorder: A Bi-National Survey and Comparison with Neurologists
por: Dent B, et al.
Publicado: (2020)

Neurobehavioral burden of multiple sclerosis with nanotheranostics
por: Sriramoju B, et al.
Publicado: (2015)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu R, et al.
Publicado: (2013)

Cannabinoids in the management of spasticity associated with multiple sclerosis
por: Anna Maria Malfitano, et al.
Publicado: (2008)

Effect of acetazolamide for long-lasting paroxysmal dystonia in a patient with multiple sclerosis: a case report and review of literature
por: Hsieh PC, et al.
Publicado: (2013)

Impact of Andropause on Multiple Sclerosis
por: Maria C. Ysrraelit, et al.
Publicado: (2021)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke C, et al.
Publicado: (2011)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Clemens Warnke, et al.
Publicado: (2009)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: David W Brandes
Publicado: (2010)

Association between smoking and cognitive impairment in multiple sclerosis
por: Özcan ME, et al.
Publicado: (2014)

Gut microbiome is associated with multiple sclerosis activity in children
por: Mary K. Horton, et al.
Publicado: (2021)

Neuropsychiatric assessments in patients with multiple sclerosis in early phases and with low disability
por: Schmidt SL, et al.
Publicado: (2018)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013)

Measuring treatment response to advance precision medicine for multiple sclerosis
por: Peter A. Calabresi, et al.
Publicado: (2021)

Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
por: Introna A, et al.
Publicado: (2018)

Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report
por: De Pasquale C, et al.
Publicado: (2014)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey D, et al.
Publicado: (2015)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop F, et al.
Publicado: (2013)

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis
por: Fabricio Gonz&aacute;lez-Andrade, et al.
Publicado: (2010)

Efficacy of a short cognitive training program in patients with multiple sclerosis
por: Pérez-Martín MY, et al.
Publicado: (2017)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij R, et al.
Publicado: (2015)

Pareidolia in Parkinson’s Disease and Multiple System Atrophy
por: Kentaro Kurumada, et al.
Publicado: (2021)

A study of patients with aggressive multiple sclerosis at disease onset
por: Kaunzner UW, et al.
Publicado: (2016)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Julie A Murphy, et al.
Publicado: (2010)